NDC-11 (Package) | NDC-9 (Product) | Generic Name (Descending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63323-0650-10 | 63323-0650 | Oxaliplatin | Oxaliplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 11, 2010 | May 21, 2015 | No Longer Used | |
63323-0650-17 | 63323-0650 | Oxaliplatin | Oxaliplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 30, 2012 | May 21, 2015 | No Longer Used | |
63323-0650-20 | 63323-0650 | Oxaliplatin | Oxaliplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 11, 2010 | May 21, 2015 | No Longer Used | |
63323-0650-27 | 63323-0650 | Oxaliplatin | Oxaliplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 30, 2012 | May 21, 2015 | No Longer Used | |
00955-1727-20 | 00955-1727 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | July 7, 2014 | Jan. 31, 2025 | In Use |
00955-1725-10 | 00955-1725 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | July 7, 2014 | July 1, 2023 | In Use |
72266-0161-01 | 72266-0161 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | March 30, 2020 | In Use | |
72266-0162-01 | 72266-0162 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | March 30, 2020 | In Use | |
45963-0611-53 | 45963-0611 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 5, 2015 | Nov. 30, 2023 | In Use |
45963-0611-59 | 45963-0611 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 5, 2015 | Aug. 31, 2024 | In Use |
71288-0171-11 | 71288-0171 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 11, 2024 | In Use | |
71288-0172-21 | 71288-0172 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 11, 2024 | In Use | |
00310-1350-30 | 00310-1350 | Osimertinib | Tagrisso | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 13, 2015 | In Use | |
00310-1350-95 | 00310-1350 | Osimertinib | Tagrisso | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | March 15, 2019 | In Use | |
00310-1349-30 | 00310-1349 | Osimertinib | Tagrisso | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov. 13, 2015 | In Use | |
78206-0148-01 | 78206-0148 | Ontruzant | Ontruzant | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | June 1, 2021 | In Use | ||
00006-5034-02 | 00006-5034 | Ontruzant | Ontruzant | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | April 15, 2020 | Sept. 30, 2023 | No Longer Used | |
54569-5873-00 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
54569-5873-01 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
54569-5873-02 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
54569-5873-03 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
54569-5873-04 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
54569-6168-00 | 54569-6168 | Ondansetron, ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 9, 2016 | In Use | |
54569-6168-01 | 54569-6168 | Ondansetron, ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 9, 2016 | In Use | |
54569-6168-02 | 54569-6168 | Ondansetron, ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 9, 2016 | In Use |
Found 10,000 results in 17 milliseconds — Export these results